切换至 "中华医学电子期刊资源库"

中华产科急救电子杂志 ›› 2023, Vol. 12 ›› Issue (04) : 206 -211. doi: 10.3877/cma.j.issn.2095-3259.2023.04.004

妊娠合并内分泌疾病

妊娠合并原发性甲状旁腺功能亢进症的诊治
钟逸锋, 高劲松()   
  1. 100730 中国医学科学院 北京协和医学院 北京协和医院妇产科 国家妇产疾病临床医学研究中心
  • 收稿日期:2023-08-02 出版日期:2023-11-18
  • 通信作者: 高劲松
  • 基金资助:
    北京协和医院中央高水平医院临床科研专项2022年专科提升项目(2022-PUMCH-B-075)

Diagnosis and treatment of pregnancy with primary hyperparathyroidism

Yifeng Zhong, Jinsong Gao()   

  • Received:2023-08-02 Published:2023-11-18
  • Corresponding author: Jinsong Gao
引用本文:

钟逸锋, 高劲松. 妊娠合并原发性甲状旁腺功能亢进症的诊治[J]. 中华产科急救电子杂志, 2023, 12(04): 206-211.

Yifeng Zhong, Jinsong Gao. Diagnosis and treatment of pregnancy with primary hyperparathyroidism[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2023, 12(04): 206-211.

原发性甲状旁腺功能亢进症(primary hyperparathyroidism,PHPT)是妊娠期罕见的合并症,发病率为0.03%~0.05%,临床表现各异,可累及多个器官和系统,某些方面与妊娠期的生理反应类似,不易区分。实验室检查表现为高钙血症、低磷血症、血甲状旁腺激素升高,孕期影像学检查首选颈部超声,可识别及定位异常甲状旁腺组织,磁共振成像检查对判断病变程度有帮助,应避免X线摄影及核素显像。手术切除病变甲状旁腺是孕期治疗PHPT的首选方案,手术时机以孕中期为宜,术后应注意预防孕妇及围产儿低钙血症。对于轻中度的PHPT可选择保守治疗,补液、扩容、利尿对于降低高钙血症有帮助,药物治疗因缺乏孕期用药的安全数据而受到严重限制。

Primary hyperparathyroidism (PHPT) is a rare complication of pregnancy. The incidence rate is about 0.03%-0.05%. The clinical manifestations are different and can involve multiple organs and systems. In some aspects, it is similar to the physiological response of pregnancy and is difficult to distinguish. The laboratory examination shows hypercalcemia, hypophosphatemia, and elevated blood PTH. Ultrasound is the preferred imaging examination during pregnancy, which can identify and locate abnormal parathyroid tissue. Magnetic resonance imaging helps determine the degree of the lesion, and X-ray imaging and nuclide imaging should be avoided. Parathyroidectomy is the first choice for the treatment of PHPT during pregnancy. The operation time should be in the second trimester of pregnancy. After the operation, attention should be paid to the prevention of hypocalcemia in pregnant women and perinatal infants. For mild to moderate PHPT, conservative management can be selected. Fluid replacement, volume expansion and diuresis are helpful in reducing hypercalcemia. Drug treatment is severely limited due to the lack of safety data for drug use during pregnancy.

[1]
Hirsch D, Kopel V, Nadler V, et al. Pregnancy outcomes in women with primary hyperparathyroidism[J]. J Clin Endocrinol Metab2015100(5):2115-2122.
[2]
中华医学会骨质疏松和骨矿盐疾病分会,中华医学会内分泌分会代谢性骨病学组. 原发性甲状旁腺功能亢进症诊疗指南[J]. 中华骨质疏松和骨矿盐疾病杂志20147(3):187-198.
[3]
Marini F, Cianferotti L, Giusti F,et al. Molecular genetics in primary hyperparathyroidism: the role of genetic tests in differential diagnosis, disease prevention strategy, and therapeutic planning. A 2017 update[J]. Clin Cases Miner Bone Metab201714(1):60-70.
[4]
Miller PD, Bilezikian JP. Bone densitometry in asymptomatic primary hyperparathyroidism[J]. J Bone Miner Res200217 Suppl 2:N98-102.
[5]
Syed Z, Khan A. Skeletal effects of primary hyperparathyroidism[J]. Endocr Pract20006(5):385-388.
[6]
Davis C, Nippita T. Hyperparathyroidism in pregnancy[J]. BMJ Case Rep202013(2):1-3.
[7]
Edling KL, Korenman SG, Janzen C, et al. A pregnant dilemma: primary hyperparathyroidism due to parathyromatosis in pregnancy[J]. Endocr Pract201420(2):e14-17.
[8]
Dale AG, Holbrook BD, Sobel L, et al. Hyperparathyroidism in pregnancy leading to pancreatitis and preeclampsia with severe features[J]. Case Rep Obstet Gynecol20172017:1-3.
[9]
Hong MK, Lin YC, Wei YC, et al. Parathyroid adenoma with hypertensive crisis and intracerebral hemorrhage mimicking hemolysis, elevated liver enzymes, low platelets syndrome[J]. Obstet Gynecol2011117(2 Pt 2):498-500.
[10]
Gennari C, Nami R, Gonnelli S. Hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-aldosterone systems[J]. Miner Electrolyte Metab199521(1-3):77-81.
[11]
Malekar-Raikar S, Sinnott BP. Primary hyperparathyroidism in pregnancy-a rare cause of life-threatening hypercalcemia: case report and literature review[J]. Case Rep Endocrinol20112011:1-6.
[12]
Ardawi MS, Nasrat HA, BA′Aqueel HS. Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: a longitudinal study[J]. Eur J Endocrinol1997137(4):402-409.
[13]
Yadav S, Yadav YS, Goel MM, et al. Calcitonin gene- and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case-control study[J]. Arch Gynecol Obstet2014290(5):897-903.
[14]
Feingold KR. Calcium and phosphate metabolism and related disorders during pregnancy and lactation[DB/OL]. South Dartmouth (MA):MDText.com, Inc,2000(2021-07-31)[2023-08-02].

URL    
[15]
Boudou P, Ibrahim F, Cormier C, et al. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism[J]. J Endocrinol Invest200629(6):511-515.
[16]
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab201196(7):1911-1930.
[17]
Kovacs CS. Calcium and bone metabolism disorders during pregnancy and lactation[J]. Endocrinol Metab Clin North Am201140(4):795-826.
[18]
Kairys JC, Daskalakis C, Weigel RJ. Surgeon-performed ultrasound for preoperative localization of abnormal parathyroid glands in patients with primary hyperparathyroidism[J]. World J Surg200630(9):1658-1663.
[19]
Vitetta GM, Neri P, Chiecchio A, et al. Role of ultrasonography in the management of patients with primary hyperparathyroidism: retrospective comparison with technetium-99m sestamibi scintigraphy[J]. J Ultrasound201417(1):1-12.
[20]
Gotway MB, Reddy GP, Webb WR, et al. Comparison between MR imaging and 99m Tc MIBI scintigraphy in the evaluation of recurrent or persistent hyperparathyroidism[J]. Radiology2001218(3):783-790.
[21]
Jain C. ACOG Committee Opinion No. 723: guidelines for diagnostic imaging during pregnancy and lactation[J]. Obstet Gynecol2019133(1):186.
[22]
American College of Obstetricians and Gynecologists′ Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation[J]. Obstet Gyneco2016127(2):e75-80.
[23]
Schnatz PF, Curry SL. Primary hyperparathyroidism in pregnancy: evidence-based management[J]. Obstet Gynecol Surv200257(6):365-376.
[24]
Rey E, Jacob CE, Koolian M, et al. Hypercalcemia in pregnancy-a multifaceted challenge: case reports and literature review[J]. Clin Case Rep20164(10):1001-1008.
[25]
Patel S, Lyons AR, Hosking DJ. Drugs used in the treatment of metabolic bone disease[J]. Drugs199346(4):594-617.
[26]
Nadarasa K, Bailey M, Chahal H, et al. The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma[J]. Endocrinol Diabetes Metab Case Rep20142014:1-4.
[27]
Vera L, Oddo S, Di Iorgi N, et al. Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature[J]. J Med Case Rep201610(1):1-5.
[28]
Horton WB, Stumpf MM, Coppock JD, et al. Gestational primary hyperparathyroidism due to ectopic parathyroid adenoma: case report and literature review[J]. J Endocr Soc20171(9):1150-1155.
[29]
Horjus C, Groot I, Telting D, et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium[J]. J Pediatr Endocrinol Metab200922(8):741-749.
[30]
Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy?[J]. J Obstet Gynaecol Can200830(12):1146-1148.
[31]
Boyce RW, Varela A, Chouinard L, et al. Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period[J]. Bone201464:314-325.
[32]
Levy HA, Pierucci L, Stroup P. Oral phosphates treatment of hypercalcemia in pregnancy[J]. J Med Soc N J198178(2):113-115.
[33]
Pothiwala P, Levine SN. Parathyroid surgery in pregnancy: review of the literature and localization by aspiration for parathyroid hormone levels[J]. J Perinatol200929(12):779-784.
[34]
Han ES, Fritton K, Bacon P, et al. Preterm parturient with polyhydramnios and pancreatitis: primary presentation of hyperparathyroidism[J]. Case Rep Obstet Gynecol20182018:1-4.
[35]
Tachamo N, Timilsina B, Dhital R, et al. Primary hyperparathyroidism in pregnancy: successful parathyroidectomy during first trimester[J]. Case Rep Endocrinol20182018:1-4.
[36]
Refardt J, Farina P, Hoesli I, et al. Hypercalcemic crisis in third trimenon: evaluating the optimal treatment strategy[J]. Gynecol Endocrinol201834(10):833-836.
[1] 李钱梅, 何冠南, 赵婧, 陈曦, 唐玉英, 马丽琼, 梁蓉, 袁桃, 李明星. 早孕期低危妊娠和高危妊娠胎盘微血流成像特征及预后分析[J]. 中华医学超声杂志(电子版), 2024, 21(07): 726-732.
[2] 刘涵, 刘晓菲, 陈翰翰, 陈延君, 张雁. 妊娠期肉芽肿性乳腺炎一例[J]. 中华乳腺病杂志(电子版), 2024, 18(04): 253-254.
[3] 于溟璇, 杜华, 张彩虹, 师迎旭. miRNA-192家族在乳腺癌中的作用机制及诊断价值[J]. 中华乳腺病杂志(电子版), 2024, 18(04): 235-240.
[4] 何淳诺, 田志敏, 李焕玺, 吴昊越, 庄凯鹏, 周胜虎, 张浩强. 小儿发育性髋关节发育不良诊治的研究进展[J]. 中华关节外科杂志(电子版), 2024, 18(04): 497-504.
[5] 张静, 刘畅, 华成舸. 妊娠期患者口腔诊疗进展[J]. 中华口腔医学研究杂志(电子版), 2024, 18(05): 340-344.
[6] 中国医师协会肝癌专业委员会. 肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)[J]. 中华普通外科学文献(电子版), 2024, 18(05): 313-324.
[7] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[8] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[9] 刘静, 徐爽, 缪亚军. 肺腺癌miR-3653表达与高危型人乳头瘤病毒感染及预后的关系[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 600-604.
[10] 甘志新, 胡雍军, 肖晶, 胡明冬. 降钙素原在脓毒血症与肺部感染中的研究进展[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 663-666.
[11] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 407-449.
[12] 胡云鹤, 周玉焯, 付瑞瑛, 于凡, 李爱东. CHS-DRG付费制度下GB1分组住院费用影响因素分析与管理策略探讨[J]. 中华临床医师杂志(电子版), 2024, 18(06): 568-574.
[13] 奚培培, 周加军. 慢性肾脏病患者肌少症机制和诊治的研究进展[J]. 中华临床医师杂志(电子版), 2024, 18(05): 491-495.
[14] 孙双权, 孙玮玮, 王勇, 方道成, 温晖. 肾脏混合性上皮和间质肿瘤一例[J]. 中华临床医师杂志(电子版), 2024, 18(05): 512-515.
[15] 朱旦华, 卢放根. 以腹水为主要特征的Castleman病16例[J]. 中华临床医师杂志(电子版), 2024, 18(05): 462-473.
阅读次数
全文


摘要